PE20130377A1 - Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion - Google Patents

Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Info

Publication number
PE20130377A1
PE20130377A1 PE2012002519A PE2012002519A PE20130377A1 PE 20130377 A1 PE20130377 A1 PE 20130377A1 PE 2012002519 A PE2012002519 A PE 2012002519A PE 2012002519 A PE2012002519 A PE 2012002519A PE 20130377 A1 PE20130377 A1 PE 20130377A1
Authority
PE
Peru
Prior art keywords
staurosporin
benzoyl
preparation
crystalline form
procedure
Prior art date
Application number
PE2012002519A
Other languages
English (en)
Spanish (es)
Inventor
Pascale Hoehn
Bernd Koch
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130377(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20130377A1 publication Critical patent/PE20130377A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE2012002519A 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion PE20130377A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07

Publications (1)

Publication Number Publication Date
PE20130377A1 true PE20130377A1 (es) 2013-04-03

Family

ID=35501294

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2012002519A PE20130377A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2009000199A PE20090433A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2005001297A PE20060947A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2009000199A PE20090433A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
PE2005001297A PE20060947A1 (es) 2004-11-05 2005-11-04 Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion

Country Status (31)

Country Link
US (2) US8198435B2 (enExample)
EP (3) EP1812448B1 (enExample)
JP (4) JP5057986B2 (enExample)
KR (3) KR101333851B1 (enExample)
CN (2) CN102993213A (enExample)
AR (1) AR052322A1 (enExample)
AU (2) AU2005300693B2 (enExample)
BR (1) BRPI0517689A (enExample)
CA (1) CA2584911C (enExample)
CY (1) CY1113059T1 (enExample)
DK (1) DK1812448T3 (enExample)
EC (1) ECSP12007431A (enExample)
ES (1) ES2388142T3 (enExample)
GT (1) GT200500311A (enExample)
HK (1) HK1211587A1 (enExample)
HR (1) HRP20120652T1 (enExample)
IL (3) IL182691A (enExample)
JO (1) JO2897B1 (enExample)
MA (1) MA29033B1 (enExample)
MX (2) MX346525B (enExample)
MY (2) MY147404A (enExample)
NO (2) NO338960B1 (enExample)
NZ (3) NZ599033A (enExample)
PE (3) PE20130377A1 (enExample)
PL (1) PL1812448T3 (enExample)
PT (1) PT1812448E (enExample)
RU (2) RU2394038C2 (enExample)
SI (1) SI1812448T1 (enExample)
TN (1) TNSN07165A1 (enExample)
TW (4) TWI530500B (enExample)
WO (1) WO2006048296A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
EP3592749A1 (en) * 2017-03-06 2020-01-15 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
US20220242880A1 (en) * 2019-06-24 2022-08-04 Dr. Reddy?s Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) * 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
US5344926A (en) 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) * 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
BR9917475B1 (pt) * 1999-08-30 2013-07-23 processo para a manufatura de compostos, e, modificação do processo.
CA2439097C (en) 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
WO2004094645A1 (en) * 2003-04-22 2004-11-04 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
RU2467012C2 (ru) 2012-11-20
TW201247680A (en) 2012-12-01
PL1812448T3 (pl) 2012-10-31
GT200500311A (es) 2006-05-22
JP2012149099A (ja) 2012-08-09
IL207702A0 (en) 2010-12-30
JP5701246B2 (ja) 2015-04-15
TNSN07165A1 (en) 2008-11-21
US8198435B2 (en) 2012-06-12
IL182691A0 (en) 2007-09-20
PE20090433A1 (es) 2009-05-05
US20090137552A1 (en) 2009-05-28
JP2008518995A (ja) 2008-06-05
RU2009137788A (ru) 2011-04-20
TWI530501B (zh) 2016-04-21
MY147404A (en) 2012-11-30
TWI530500B (zh) 2016-04-21
RU2007120695A (ru) 2008-12-10
EP2955186A1 (en) 2015-12-16
WO2006048296A1 (en) 2006-05-11
NO340404B1 (no) 2017-04-18
MY154878A (en) 2015-08-14
MX346525B (es) 2017-03-23
PT1812448E (pt) 2012-08-24
EP2272850A3 (en) 2011-09-21
AU2009245817A1 (en) 2009-12-24
BRPI0517689A (pt) 2008-10-14
US8710216B2 (en) 2014-04-29
JP2015063569A (ja) 2015-04-09
EP1812448B1 (en) 2012-05-23
TWI433852B (zh) 2014-04-11
NO20072290L (no) 2007-05-30
HRP20120652T1 (hr) 2012-09-30
EP1812448A1 (en) 2007-08-01
NO20161152A1 (no) 2007-05-30
US20120322789A1 (en) 2012-12-20
IL217571A (en) 2017-07-31
AR052322A1 (es) 2007-03-14
PE20060947A1 (es) 2006-10-30
JP2017061578A (ja) 2017-03-30
KR20070083979A (ko) 2007-08-24
KR101289998B1 (ko) 2013-07-30
CN102993213A (zh) 2013-03-27
AU2005300693B2 (en) 2010-08-19
NO338960B1 (no) 2016-11-07
HK1211587A1 (en) 2016-05-27
SI1812448T1 (sl) 2012-09-28
TW200628474A (en) 2006-08-16
JO2897B1 (en) 2015-09-15
TW201446773A (zh) 2014-12-16
AU2005300693A1 (en) 2006-05-11
MA29033B1 (fr) 2007-11-01
EP2272850A2 (en) 2011-01-12
NZ599033A (en) 2012-09-28
DK1812448T3 (da) 2012-08-27
NZ588025A (en) 2012-04-27
KR101333851B1 (ko) 2013-11-27
IL182691A (en) 2013-02-28
ECSP12007431A (es) 2012-06-29
TW201247681A (en) 2012-12-01
TWI455941B (zh) 2014-10-11
KR20120101600A (ko) 2012-09-13
CN102627658A (zh) 2012-08-08
AU2009245817B2 (en) 2013-02-21
CA2584911A1 (en) 2006-05-11
KR101265850B1 (ko) 2013-05-20
EP2272850B1 (en) 2017-05-10
JP5057986B2 (ja) 2012-10-24
HK1108881A1 (en) 2008-05-23
CY1113059T1 (el) 2016-04-13
CA2584911C (en) 2017-10-24
KR20120101601A (ko) 2012-09-13
RU2394038C2 (ru) 2010-07-10
NZ554653A (en) 2010-10-29
MX2007005429A (es) 2007-05-18
ES2388142T3 (es) 2012-10-09
IL207702A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
ES2620442T3 (es) Uso de derivados de tetraquis(N-alquilpiridinio)-porfirina para la destrucción de microbios o la prevención de su crecimiento
ES2502472T3 (es) Composición adhesiva para su uso en un inmunosensor
PE20130377A1 (es) Forma cristalina (ii) de n-benzoil-estaurosporina y procedimiento para su preparacion
CL2010000516A1 (es) Composicion fungicida sin solvente que comprende estrobirulina insoluble en agua dispersado a traves del material portador en forma nano-dispersa teniendo un diametro pico de la forma nano-dispersa menor a 1000 nm; proceso para preparar dicha composicion; uso de dicha composicion para tratar una infestacion (divisional de la sol. 2030-07).
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
AR056055A1 (es) Complejos cristalinos e hidratos de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
LU92550I2 (fr) Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2007002919A1 (es) Compuestos derivados de pirido[2,3-b]indol, inhibidores de quinasa; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar cancer, entre otras enfermedades.
AR060264A1 (es) Composicion farmaceutica que contiene lactato y calcio, usos de dicha composicion y metodo de preparacion
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
AR063792A1 (es) Uso de copolimerizados de bloques a base de vinillactamas y acetato de vinilo como solubilizantes
CO6400226A2 (es) Micrólido anti-inflamatorio
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
WO2006081008A3 (en) Nucleic acids for apoptosis of cancer cells
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
NO20040614L (no) Preparater som inneholder konjugert linolalkohol.
AR042712A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes por incremento de la cantidad de celulas de los islotes de langerhans
AR065068A1 (es) Composicion farmaceutica que comprende tramadol y ketoprofeno en asociacion
NI200600146A (es) Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso
WO2007121054A3 (en) Nucleic acids for apoptosis of cancer cells
AR058361A1 (es) Composiciones lifolizadas de un compuesto de triazolopirimidina
PE20070548A1 (es) Formas cristalinas de la sal de di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico

Legal Events

Date Code Title Description
FC Refusal